SKOKIE, Ill.--(BUSINESS WIRE)--Sep. 28, 2018--
Exicure,
Inc. (OTCQB:XCUR), the pioneer in the development and application of
three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene
regulatory and immunotherapeutic agents, announced today that Dr. David
Giljohann, Chief Executive Officer of Exicure, will present at the
Ladenburg Thalmann 2018 Healthcare Conference and Leerink Partners
Roundtable Series: Rare Disease & Oncology. Details of these
presentations are as follows:
Ladenburg Thalmann 2018 Healthcare Conference
-
Date/Time: Tuesday, October 2, 2018 at 2:00 p.m. EDT
-
Location: Sofitel Hotel, New York City
Leerink Partners Roundtable Series: Rare Disease & Oncology
-
Date/Time: Wednesday, October 3, 2018 at 9:30 a.m. EDT
-
Location: Lotte New York Palace, New York City
A live webcast of these presentations will be available on the Events
& Presentations section of Exicure's website, where it will also
be archived and available for replay following the presentation for 30
days.
About Exicure, Inc.
Exicure, Inc. is a clinical stage biotechnology company developing a new
class of immunomodulatory and gene regulating drugs against validated
targets. Exicure's proprietary 3-dimensional, spherical nucleic acid
(SNA™) architecture unlocks the potential of therapeutic
oligonucleotides in a wide range of cells and tissues. Exicure's lead
programs address oncology, inflammatory diseases and genetic disorders.
Exicure is based outside of Chicago, IL. For more information, please
visit www.exicuretx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005054/en/
Source: Exicure, Inc.
Media Contact:
MacDougall Biomedical Communications
Karen
Sharma, 781-235-3060
ksharma@macbiocom.com
or
Investor
Contact:
The Del Mar Consulting Group, Inc.
Robert B.
Prag, 858-794-9500
President
bprag@delmarconsulting.com